As there are known connections between lipogenesis and the UPR (Figure 2), particularly via the IRE1/XBP-1 axis [79], and that link extends to FASN [80], combination therapies that disrupt long chain fatty acid synthesis in conjunction with targets involved in the UPR may have value in future GBM treatment strategies. Here, XBP1 is linked to glioblastoma.